Literature DB >> 25628507

Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.

William R Truong, Jason J Schafer, William R Short.   

Abstract

Once-daily, single-tablet regimens have become integral to the management of human immunodeficiency virus type 1 infection, partly because they may improve adherence due to a lower pill burden. This article reviews the single-tablet options.

Entities:  

Year:  2015        PMID： 25628507      PMCID： PMC4296592     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  72 in total

1.  Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

Authors:  Parul Patel; Ivy Song; Julie Borland; Apurva Patel; Yu Lou; Shuguang Chen; Toshihiro Wajima; Amanda Peppercorn; Sherene S Min; Stephen C Piscitelli
Journal:  J Antimicrob Chemother       Date:  2011-04-14       Impact factor: 5.790

2.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Authors:  Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

3.  Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Authors:  Kelly E Dooley; Patrick Sayre; Julie Borland; Elizabeth Purdy; Shuguang Chen; Ivy Song; Amanda Peppercorn; Stephanie Everts; Stephen Piscitelli; Charles Flexner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

4.  Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers.

Authors:  Bharat Damle; Robert LaBadie; Penelope Crownover; Paul Glue
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

5.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Edwin DeJesus; Jürgen K Rockstroh; Keith Henry; Jean-Michel Molina; Joseph Gathe; Srinivasan Ramanathan; Xuelian Wei; Kitty Yale; Javier Szwarcberg; Kirsten White; Andrew K Cheng; Brian P Kearney
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

Review 6.  Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.

Authors:  Bhavik M Shah; Jason J Schafer; Joseph A Desimone
Journal:  Pharmacotherapy       Date:  2013-12-18       Impact factor: 4.705

7.  Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.

Authors:  Herta M Crauwels; Rolf P G van Heeswijk; Annemie Buelens; Marita Stevens; Richard M W Hoetelmans
Journal:  Int J Clin Pharmacol Ther       Date:  2014-02       Impact factor: 1.366

8.  Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.

Authors:  Alberto Matteelli; Mario Regazzi; Paola Villani; Giuseppina De Iaco; Maria Cusato; Anna Cristina C Carvalho; Silvio Caligaris; Lina Tomasoni; Maria Manfrin; Susanna Capone; Giampiero Carosi
Journal:  Curr HIV Res       Date:  2007-05       Impact factor: 1.581

9.  Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.

Authors:  Jeonnette R Ickovics; Ann Cameron; Robert Zackin; Roland Bassett; Margaret Chesney; Victoria A Johnson; Daniel R Kuritzkes
Journal:  Antivir Ther       Date:  2002-09

Review 10.  Applications of CYP450 testing in the clinical setting.

Authors:  C F Samer; K Ing Lorenzini; V Rollason; Y Daali; J A Desmeules
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074
View more
  13 in total

Review 1.  The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.

Authors:  Upal Roy; Jesse Rodríguez; Paul Barber; José das Neves; Bruno Sarmento; Madhavan Nair
Journal:  Nanomedicine (Lond)       Date:  2015-09-24       Impact factor: 5.307

2.  National characteristics and trends in antiretroviral treatment in Australia can be accurately estimated using a large clinical cohort.

Authors:  Robin Huang; Kathy Petoumenos; Richard T Gray; Hamish McManus; Nila Dharan; Rebecca Guy; David A Cooper
Journal:  J Clin Epidemiol       Date:  2018-04-25       Impact factor: 6.437

3.  Trends in ART Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the United States, 2009-2013.

Authors:  Linda Beer; Christine L Mattson; Heather Bradley; Roy L Shouse
Journal:  J Acquir Immune Defic Syndr       Date:  2017-09-01       Impact factor: 3.731

4.  "Worn out": Coping strategies for managing antiretroviral treatment fatigue among urban people of color living with HIV who were recently disengaged from outpatient HIV care.

Authors:  J Jaiswal; M D Francis; S N Singer; K B Dunlap; A B Cox; R Greene
Journal:  J HIV AIDS Soc Serv       Date:  2020-05-20

5.  The Impact of Substance Use on Adherence to Antiretroviral Therapy Among HIV-Infected Women in the United States.

Authors:  Yuehan Zhang; Tracey E Wilson; Adebola Adedimeji; Daniel Merenstein; Joel Milam; Jennifer Cohen; Mardge Cohen; Elizabeth T Golub
Journal:  AIDS Behav       Date:  2018-03

6.  Comparative study of antiretroviral drug regimens and drug-drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea.

Authors:  Mi Seon Park; Young-Mo Yang; Ju-Sin Kim; Eun Joo Choi
Journal:  Ther Clin Risk Manag       Date:  2018-11-12       Impact factor: 2.423

7.  Substance use and its effect on antiretroviral treatment adherence among male fisherfolk living with HIV/AIDS in Uganda.

Authors:  Katelyn M Sileo; Williams Kizito; Rhoda K Wanyenze; Harriet Chemusto; Elizabeth Reed; Jamila K Stockman; William Musoke; Barbara Mukasa; Susan M Kiene
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

Review 8.  Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.

Authors:  Ruben van der Galiën; Rob Ter Heine; Rick Greupink; Stein J Schalkwijk; Antonius E van Herwaarden; Angela Colbers; David M Burger
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

9.  Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India.

Authors:  A Dravid; T P Betha; A K Sharma; R Gawali; U Mahajan; M Kulkarni; C Saraf; S Kore; M Dravid; N Rathod
Journal:  HIV Med       Date:  2020-07-20       Impact factor: 3.180

10.  Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural KwaZulu Natal South Africa: A DO-ART Trial Sub-study.

Authors:  Nsika Sithole; Resign Gunda; Olivier Koole; Meighan Krows; Torin Schaafsma; Mosa Moshabela; Mark J Siedner; Connie Celum; Ruanne V Barnabas
Journal:  AIDS Behav       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.